ArticleTargeted oncology2022

Efficacy and Safety of Immunotherapy-Based Combinations as First-Line Therapy for Metastatic Renal Cell Carcinoma in Patients Who Do Not Meet Trial Eligibility Criteria.

Yuki Nemoto et al.PubMed ↗Publisher ↗

No numbers read from the abstract.